Effectiveness and safety of repeated photodynamic therapy in recurrent central serous chorioretinopathy.

IF 3 3区医学 Q1 OPHTHALMOLOGY

Acta Ophthalmologica Pub Date : 2025-05-02 DOI:10.1111/aos.17511

F M van den Tillaart, A Komrojan, C B Hoyng, J P Martinez Ciriano, S Yzer

{"title":"Effectiveness and safety of repeated photodynamic therapy in recurrent central serous chorioretinopathy.","authors":"F M van den Tillaart, A Komrojan, C B Hoyng, J P Martinez Ciriano, S Yzer","doi":"10.1111/aos.17511","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate anatomical and functional outcomes after a second photodynamic therapy (PDT) in patients with central serous chorioretinopathy (CSC), who had a recurrence of subretinal fluid (SRF) after a previously successful PDT.Methods: In this multicentre retrospective cohort study, we included patients with CSC who underwent a second PDT because of a recurrence of SRF after an effective first PDT with complete SRF resolution. Diagnosis of CSC was based on multimodal imaging. We evaluated the complete resolution rate of SRF after a second PDT with reduced settings. Also, visual acuity (VA), subfoveal ellipsoid zone (EZ) and subfoveal external limiting membrane (ELM) integrity before and after the first and the second PDT were studied.Results: A total of 88 patients were studied, of whom 18% were female. The mean age was 51.3 ± 10.5 years at the second PDT. At the first follow-up visit after the second PDT (median of 44 days [IQR 40-51] after PDT), a complete resolution of SRF occurred in 64% of eyes. The median VA was 0.15 LogMAR before the second PDT and improved to 0.05 LogMAR (p < 0.001) after PDT. The EZ was continuous in 3% of patients before the second PDT, and EZ continuity increased to 27% at the first follow-up visit after PDT. No new atrophy was observed after the second PDT.Conclusion: A second PDT with reduced settings in recurrent CSC is effective and safe in the short term, as significant anatomical and functional improvement was observed.","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Ophthalmologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/aos.17511","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate anatomical and functional outcomes after a second photodynamic therapy (PDT) in patients with central serous chorioretinopathy (CSC), who had a recurrence of subretinal fluid (SRF) after a previously successful PDT.

Methods: In this multicentre retrospective cohort study, we included patients with CSC who underwent a second PDT because of a recurrence of SRF after an effective first PDT with complete SRF resolution. Diagnosis of CSC was based on multimodal imaging. We evaluated the complete resolution rate of SRF after a second PDT with reduced settings. Also, visual acuity (VA), subfoveal ellipsoid zone (EZ) and subfoveal external limiting membrane (ELM) integrity before and after the first and the second PDT were studied.

Results: A total of 88 patients were studied, of whom 18% were female. The mean age was 51.3 ± 10.5 years at the second PDT. At the first follow-up visit after the second PDT (median of 44 days [IQR 40-51] after PDT), a complete resolution of SRF occurred in 64% of eyes. The median VA was 0.15 LogMAR before the second PDT and improved to 0.05 LogMAR (p < 0.001) after PDT. The EZ was continuous in 3% of patients before the second PDT, and EZ continuity increased to 27% at the first follow-up visit after PDT. No new atrophy was observed after the second PDT.

Conclusion: A second PDT with reduced settings in recurrent CSC is effective and safe in the short term, as significant anatomical and functional improvement was observed.

查看原文本刊更多论文

反复光动力治疗复发性中枢性浆液性脉络膜视网膜病变的有效性和安全性。

目的：评估中枢性浆液性脉络膜视网膜病变（CSC）患者第二次光动力治疗（PDT）后的解剖和功能结果，这些患者在先前成功的PDT后视网膜下液（SRF）复发。方法：在这项多中心回顾性队列研究中，我们纳入了因第一次有效PDT后SRF复发而接受第二次PDT的CSC患者，SRF完全消退。CSC的诊断是基于多模态成像。我们评估了第二次PDT后SRF的完全分辨率。并对第一次和第二次PDT前后的视敏度（VA）、中央凹下椭球区（EZ）和中央凹下外限制膜（ELM）完整性进行了研究。结果：共纳入88例患者，其中女性占18%。第二次PDT的平均年龄为51.3±10.5岁。在第二次PDT后的第一次随访中（PDT后中位44天[IQR 40-51]）， 64%的眼睛完全消除了SRF。第二次PDT前的中位VA为0.15 LogMAR，改善至0.05 LogMAR (p)。结论：由于观察到明显的解剖和功能改善，复发性CSC的第二次PDT减少设置在短期内是有效和安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Ophthalmologica 医学-眼科学

CiteScore

7.60

自引率

5.90%

发文量

433

审稿时长

6 months

期刊介绍： Acta Ophthalmologica is published on behalf of the Acta Ophthalmologica Scandinavica Foundation and is the official scientific publication of the following societies: The Danish Ophthalmological Society, The Finnish Ophthalmological Society, The Icelandic Ophthalmological Society, The Norwegian Ophthalmological Society and The Swedish Ophthalmological Society, and also the European Association for Vision and Eye Research (EVER). Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses.